Select Page

Ongoing Studies

San Antonio Eye Specialists is currently conducting clinical studies for certain medications and the side effect, macular edema in conjunction with leading San Antonio neurologist, Ann Bass, M.D. One study is conducted by Novartis for the medication Gilenya or the generic Fingolimod for Multiple Sclerosis (MS) and the other is by Pfiser for the medication Lyrica or the generic Pregabalin for Epilepsy.

These studies observe the effects of Gilenya / Fingolimod and Lyrica / Pregabalin on the eye for signs of macular edema.

Macular edema occurs when fluid and protein particles build up on or under the eye’s macula (the center portion of the ocular retina) which in turn, causes swelling. This swelling can cause a distortion in a patient’s central vision.

Patients that take Gilenya, Lyrica or the generics Fingolimod or Pregabalin may or may not develop macular edema.

If you take these medications and wish to enroll in our San Antonio study, please contact our office. We will be happy to schedule an appointment. Our study coordinator Ray Marino of San Antonio Eye Specialists can be reached at (210) 822-9800, Ext 107.

Patient satisfaction and overall results when comparing Contact Lens wear to LASIK.; Cornea Research Foundation of America.Prospective randomized 12-week controlled study of visual field change in subjects with partial seizures receiving pregabalin or placebo.



A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of siponimod (BAF312) in patients with secondary progressive multiple sclerosis


A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis


A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a (Rebif ) in patients with relapsing multiple sclerosis.